Biotech RadarJobs updated

COMPANY

Corvus Pharmaceuticals

HQ: South San Francisco, CA source · corvuspharma.com ↗ · West Coast

Clinical Phase 3

Keywords: oncology cancer T-Cell Lymphoma Atopic Dermatitis Renal Cell Cancer Metastatic Castration Resistant Prostate Cancer Covid-19 Not Otherwise Specified Peripheral T-Cell Lymphoma Angioimmunoblastic T-cell Lymphoma Follicular T-Cell Lymphoma Nodal Peripheral T-Cell Lymphoma With TFH Phenotype Systemic Anaplastic Large Cell Lymphoma Lymphoma, T-Cell, Peripheral Hidradenitis Suppurativa Atopic Dermatitis Eczema Eczema Atopic Eczema Non-Small Cell Lung Cancer Colorectal Cancer Triple Negative Breast Cancer Cervical Cancer Ovarian Cancer Pancreatic Cancer Endometrial Cancer Sarcoma Squamous Cell Carcinoma of the Head and Neck Bladder Cancer Non-hodgkin Lymphoma Multiple Myeloma Soquelitinib CPI-006 CPI-818 CPI-444

Location: South San Francisco, CA · source · Aug 6, 2026

Profile checked Oct 10, 2026

$201.0MRaised (2 yrs)11Trials (company is sponsor)

Timeline

  1. Trial start Phase 1: Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa source ↗
  2. Trial start Phase 2: Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD source ↗
  3. Raise Follow-on offering: $201M (total, as published), announced Jan 23, 2026. Source: company release on GlobeNewswire. source ↗
  4. Trial start Phase 3: Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large- source ↗
  5. Trial start Phase 1: Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD source ↗
  6. Trial start Phase 3: CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients source ↗
  7. Trial start Phase 1: Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients source ↗
  8. Trial start Phase 1: Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma source ↗
  9. Trial start Phase 1: A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma source ↗
  10. Trial start Phase 1: CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers source ↗
  11. Trial start Phase 1: Study to Evaluate the Pharmacokinetics of a New Tablet Formulation of CPI-444 in Fed and Fasted Healthy Male and Female Subjects source ↗
  12. Trial start 1: Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $201.0M. Last 2 years.

Clinical trials (lead sponsor) 11

RecordTitlePhaseStatusStartPrimary completion
NCT06561048Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell LymphomaPhase 3RecruitingOct 2, 20242027-11 (estimated)
NCT07828860Safety and Efficacy of Soquelitinib in Adults With Hidradenitis SuppurativaPhase 1RecruitingSep 17, 20262027-12 (estimated)
NCT06345404Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe ADPhase 1CompletedApr 16, 2024Jan 28, 2026 (actual)
NCT07441395Study to Evaluate Soquelitinib in Participants With Moderate to Severe ADPhase 2Recruiting2026-022027-06 (estimated)
NCT03952078A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell LymphomaPhase 1Active, not recruitingMay 3, 2019Apr 30, 2026 (estimated)
NCT03454451CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced CancersPhase 1CompletedApr 25, 2018Dec 28, 2022 (actual)
NCT04734873CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 PatientsPhase 3TerminatedFeb 25, 2021Aug 18, 2021 (actual)
NCT04280328Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple MyelomaPhase 1CompletedFeb 20, 2020Sep 21, 2021 (actual)
NCT02655822Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers1Completed2016-012021-06 (actual)
NCT04464395Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 PatientsPhase 1CompletedJul 1, 2020Mar 1, 2021 (actual)
NCT03237988Study to Evaluate the Pharmacokinetics of a New Tablet Formulation of CPI-444 in Fed and Fasted Healthy Male and Female SubjectsPhase 1CompletedJul 20, 2017Sep 20, 2017 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback